Sweden · Delayed Price · Currency is SEK Integrum AB Earnings Call Transcripts
Fiscal Year 2026
-
Transitioned to a commercial focus with strong US growth and a SEK 42M rights issue. Gross margin fell due to US tariffs, and cost-saving measures are underway to reach positive cash flow within 12–15 months.
-
Sales grew 28.9% year-over-year, led by 41% growth in the U.S., with gross margin impacted by tariffs. S1 surgeries rose 10% to 41, and new distribution agreements and sponsorships are expanding global reach.
Fiscal Year 2025
-
Q3 net sales fell 21% year-over-year, mainly due to prior year one-offs in EMEA/APAC, while U.S. sales remained stable. Strategic focus is on U.S. market adoption, cost control, and prioritizing projects with clear ROI, supported by new financing and partnerships.
-
Q2 saw a 21% year-over-year revenue decline and negative EBIT, but sequential growth was achieved through increased S1 procedures and Axor sales. Strategic focus is on U.S. and select European markets, commercial execution, and portfolio prioritization, with ongoing efforts to address insurance and competitive challenges.
-
Q1 net sales declined 9.5% year-over-year to SEK 18.5 million, with negative EBIT and higher costs. Strategic partnerships, especially with Hanger, and a capital injection are expected to drive future growth, while the company expands its sales force and market reach.
Fiscal Year 2024
-
Management is prioritizing sales force productivity, targeted product launches, and operational discipline to restore growth and shareholder value. Q1 saw a 9.5% sales decline, with new strategies focused on prosthetist engagement and insurance challenges.